Condition: Non-Small-Cell Lung Cancer · Metastatic Non-Small-Cell Lung Cancer · Advanced Non-Small-Cell Lung Cancer · Sponsor: ArriVent BioPharma, Inc.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.
This description comes directly from the study's public registry record.
Vanessa Esquibel · 619-540-3451 · FURMO006CT@arrivent.com
Always discuss trial participation with your own doctor first.
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| UCSF Medical Center-Mission Bay | San Francisco, California, United States | Recruiting |
| Kaiser Permanente Medical Center | Vallejo, California, United States | Recruiting |
| University of Colorado Health | Aurora, Colorado, United States | Recruiting |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Recruiting |
| University of Illinois Hospital and Health Sciences Systems | Chicago, Illinois, United States | Recruiting |
| Northwell Health/R.J. Zuckerberg Cancer Center | Lake Success, New York, United States | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
| Ohio State University Hospitals | Columbus, Ohio, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Oncology | Dallas, Texas, United States | Recruiting |
+ 66 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07185997